TAFA4 Inhibitors
Chemical inhibitors of TAFA4 can impede its function through various molecular mechanisms. PD 98059 and U0126 target the MAPK/ERK pathway, which is integral to the regulation of TAFA4. By selectively inhibiting MEK, both PD 98059 and U0126 can reduce ERK activation, leading to a downstream decrease in TAFA4 activity. Similarly, LY294002 and Wortmannin, as inhibitors of phosphoinositide 3-kinases (PI3K), can interrupt upstream signaling that may regulate TAFA4 function. Since PI3K is a key player in several signal transduction pathways, its inhibition can result in a reduced activation of TAFA4. SB203580 and SP600125 work on different nodes within the MAPK network. SB203580 specifically inhibits p38 MAP kinase, and SP600125 targets c-Jun N-terminal kinase (JNK). Both kinases are involved in cellular responses to various stimuli, and their inhibition can alter the signaling events that normally lead to TAFA4 activation.
The chemical Rapamycin inhibits the mTOR pathway, which has links to TAFA4 activity regulation. Inhibition of mTOR by Rapamycin can lead to changes in TAFA4 function. Brefeldin A disrupts vesicle trafficking by inhibiting ADP-ribosylation factor (ARF), which can affect the intracellular localization and, consequentially, the function of TAFA4. Inhibitors like Go6976 and GF109203X target protein kinase C (PKC), a kinase involved in a plethora of signaling pathways. Inhibition of PKC can decrease the activation of signaling cascades that involve TAFA4. Y-27632, acting as a ROCK inhibitor, impedes the Rho-associated protein kinase, which is connected to the regulation of cytoskeleton dynamics-a process that can influence TAFA4 function. Lastly, Dasatinib, as a Src family kinase inhibitor, can lead to the downregulation of Src kinase-mediated pathways, resulting in a decrease in TAFA4 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a component of the MAPK/ERK pathway. By inhibiting MEK, PD 98059 can reduce ERK activation. Since TAFA4 has been shown to be influenced by the ERK signaling pathway, the inhibition of this pathway would result in the functional inhibition of TAFA4. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor which prevents the activation of MAPK/ERK pathway. Given that TAFA4 activity is modulated by the ERK pathway, U0126 would inhibit the signaling events that lead to TAFA4 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling can be upstream of pathways regulating TAFA4, thus LY294002 inhibition of PI3K could downregulate the pathway's activity, leading to decreased TAFA4 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and it works by covalently binding to the catalytic site of the enzyme. This inhibition can reduce the activity of downstream pathways that control TAFA4, inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in cellular responses to cytokines and stress. Inhibition of p38 MAP kinase can interfere with pathways that activate TAFA4, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the stress-activated MAPK pathway. Inhibition of JNK by SP600125 would inhibit signaling pathways that could activate TAFA4, thus inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), a central cell growth regulator. mTOR signaling has connections to pathways involving TAFA4, and its inhibition by rapamycin would lead to functional inhibition of TAFA4. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which is involved in vesicle trafficking within cells. By inhibiting ARF, Brefeldin A can disrupt the intracellular transport processes that are necessary for the proper localization and function of TAFA4. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Go6976 is a potent protein kinase C (PKC) inhibitor. Since PKC is involved in multiple signaling pathways, its inhibition by Go6976 could lead to a reduction in TAFA4 activity by decreasing the activation of pathways that TAFA4 is a part of. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is another potent and selective inhibitor of PKC. By specifically inhibiting PKC isoforms, GF109203X would suppress the activation of signaling cascades that lead to the activation and function of TAFA4. | ||||||